Yvonne McGrath
Directeur Technique/Scientifique/R&D chez ITEOS THERAPEUTICS, INC.
Fortune : 518 940 $ au 31/05/2024
Profil
Yvonne McGrath is currently the Chief Scientific Officer at iTeos Therapeutics, Inc. She previously worked as the Director & Chief Scientific Officer at Complix NV from 2014 to 2020.
Prior to that, she held the position of Head-Development at Immunocore Holdings Plc and Immunocore Ltd.
from 2010 to 2014.
Dr. McGrath completed her undergraduate degree at Queen's University Belfast and obtained a doctorate from Cardiff University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ITEOS THERAPEUTICS, INC.
0,09% | 07/03/2024 | 31 000 ( 0,09% ) | 518 940 $ | 31/05/2024 |
Postes actifs de Yvonne McGrath
| Sociétés | Poste | Début |
|---|---|---|
| ITEOS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/05/2020 |
Anciens postes connus de Yvonne McGrath
| Sociétés | Poste | Fin |
|---|---|---|
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Directeur Technique/Scientifique/R&D | 01/04/2020 |
| IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | 01/04/2014 |
Immunocore Ltd.
 Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Corporate Officer/Principal | 01/04/2014 |
Formation de Yvonne McGrath
| Queen’S University Belfast | Undergraduate Degree |
| Cardiff University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| ITEOS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Health Technology |
